Skip to main content

Table 4 Safety and Efficacy Outcomes

From: Comparison of anticoagulated versus non-anticoagulated patients with intra-aortic balloon pumps

  Heparin group (n = 82) Non-heparin group (n = 65) Unadjusted p value Adjusted* odds ratio (95% CIa) Adjusted* p value
Main bleeding endpoint 17 (20.7) 13 (20.0) 0.91 0.80 (0.31–2.09) 0.65
Major access site bleeding 2 (2.4) 3 (4.6) 0.47   
Minor access site bleeding 4 (4.9) 5 (7.7) 0.51   
Major non-access site bleeding 3 (3.7) 3 (4.7) 1   
Minor non-access site bleeding 7 (8.5) 1 (1.5) 0.08   
Main thrombotic endpoint 6 (7.3) 5 (7.7) 1 1.62 (0.42–6.3) 0.42
Limb ischemia 3 (3.7) 1 (1.5) 0.63   
Device thrombosis 1 (1.2) 0 N/A   
Venous thromboembolism 1 (1.2) 2 (3.1) 0.58   
Ischemic stroke 1 (1.2) 2 (3.1) 0.58   
  1. All values are n(%)
  2. aconfidence interval
  3. *A post hoc multivariate logistic regression was performed for major composite endpoints adjusting for sex, creatinine clearance, use of dual antiplatelet therapy, and patient’s location (coronary care unit versus cardiac surgery unit)